Abivax SA

Abivax SA’s rising market sentiment stems from its growing anti‑viral pipeline and strategic collaborations, positioning it as a key player in global infectious disease therapeutics.

Abivax denies AstraZeneca takeover rumors, focusing on its pipeline of HIV, hepatitis B, and other infectious disease therapies.

Abivax’s obefazimod shows early anti‑fibrotic and symptomatic benefits in Crohn’s, with strong safety and regulatory progress highlighted at ECCO 2026.

Abivax SA’s advancing HIV, hepatitis B and other antiviral pipeline, coupled with takeover speculation, is driving investor optimism and share‑price momentum.

Abivax SA, a Paris‑based biotech, is pushing anti‑viral therapy and vaccine development, with key Phase II candidates like ABX 464 for HIV and ABX 203 for hepatitis B, while navigating volatile market trends.

Abivax SA

Abivax SA: How a French biotech’s anti‑viral pipeline is riding a health‑care rotation and what clinical milestones could spark its next growth surge.

Abivax SA sees renewed investor confidence as Truist Securities issues a buy rating, backed by a strong pipeline of antiviral and therapeutic vaccines targeting high‑growth markets in Asia and Latin America.

Abivax SA successfully raised $747.5 million in capital and saw its stock price surge 586% after announcing positive Phase-3 data for its Colitis Ulcerosa treatment candidate.

Abivax SA’s stock surged by 48% after positive late-stage trial results for its ulcerative colitis treatment, obefazimod, and a significant capital increase.